NLRP1 and NLRP3 polymorphisms in mesothelioma patients and asbestos exposed individuals a population-based autopsy study from North East Italy

Infectious Agents and Cancer

Sergio Crovella²  Elisa Trevisan³  Ronal R Moura¹  Violetta Borelli³ 

[1] Department of Genetics, Federal University of Pernambuco, Recife, Brazil;Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy;Department of Life Sciences, University of Trieste, Trieste, Italy

关键词: Haplotypes;    Asbestos exposure;    NLRP1 and NLRP3 polymorphisms;    Inflammasome;    Mesothelioma;   

Others  :  1221520
DOI  :  10.1186/s13027-015-0022-0

 received in 2015-05-14, accepted in 2015-07-20,  发布年份 2015

【 摘 要 】

NRLP1 (rs12150220, rs9889625, rs9900356, rs6502867, rs2670660) and NLRP3 (rs35829419, rs10754558) polymorphisms have been analyzed in 69 subjects with documented asbestos exposure and death for malignant pleural mesothelioma and 59 patients with documented asbestos exposure but death for other causes, all from a North East Italy. No association was found between NLRP1 and NLRP3 polymorphisms and susceptibility to develop mesothelioma using the general, dominant or recessive models. Also haplotype analysis did not reveal any significant association with mesothelioma. Our findings, being controversial with respect to another study on Italian patients, do suggest the need of further studies to unravel the contribution of NLRP1 and NLRP3 in susceptibility to mesothelioma.

【 授权许可】

   
2015 Borelli et al.

【 参考文献 】

• [1]Dostert C, Pétrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J: Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science. 2008, 320:674.
• [2]Hillegass JM, Miller JM, MacPherson MB, Westbom CM, Sayan M, Thompson JK, et al.: Asbestos and erionite prime and activate the NLRP3 inflammasome that stimulates autocrine cytokine release in human mesothelial cells. Part Fibre Toxicol. 2013, 10:39. BioMed Central Full Text
• [3]Mossman BT, Shukla A, Heintz NH, Verschraegen CF, Thomas A, Hassan R: New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas. Am J Pathol. 2013, 182:1065.
• [4]Carbone M, Yang H: Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma. Clin Cancer Res. 2012, 18:598.
• [5]Guo G, Chmielecki J, Goparaju C, Heguy A, Dolgalev I, Carbone M, et al.: Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 2015, 75:264.
• [6]Panagopoulos I, Gorunova L, Davidson B, Heim S: Novel TNS3-MAP3K3 and ZFPM2-ELF5 fusion genes identified by RNA sequencing in multicystic mesothelioma with t(7;17)(p12;q23) and t(8;11)(q23;p13). Cancer Lett. 2015, 357:502.
• [7]Matullo G, Guarrera S, Betti M, Fiorito G, Ferrante D, Voglino F, et al.: Genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study. PLoS One 2013, 8(4):e61253.
• [8]Girardelli M, Maestri I, Rinaldi RR, Tognon M, Boldorini R, Bovenzi M, et al.: NLRP1 polymorphisms in patients with asbestos-associated mesothelioma. Infect Agent Cancer. 2012, 7:25. BioMed Central Full Text